Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

计划入组 161 人 · 首次发布于 2022 年 5 月 19 日

Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration

计划入组 988 人 · 首次发布于 2013 年 8 月 2 日

The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)

计划入组 66 人 · 首次发布于 2020 年 9 月 25 日

undisclosed tyrosine kinase inhibitor (Durasert, wet age-related macular degeneration)

RAGE-immunoglobulin fusion protein (diabetes/Dry and Wet age related macular degeneration/Covid-19)

Pegaptanib

Optiva Inc

Australia

Ocugen

United States

NEW AGE VENTURES LLC

United States

FDA Approves First CRISPR-Cas13 RNA Editing Trial for Wet Age-Related Macular Degeneration

Merck Initiates Pivotal Phase 2b/3 Trial for Novel Bispecific Antibody MK-8748 in Wet Age-Related Macular Degeneration

UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration